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Introduction: Conventional treatment strategies for Temo-
zolomide (TMZ)-resistant high-grade gliomas have been
uniformly dismal. Our previous studies have shown that
TMZ-resistant tumors upregulate stress-associated NKG2D
ligands (NKG2DL) during the ﬁrst several hours following
exposure to TMZ, thereby creating an opportunity for
NKG2DL-directed cell therapy, particularly ex vivo expanded/
activated gd T cells and NK cells that directly recognize
these stress-associated antigens. Using a human/mouse
primary xenograft model, we report improved survival
using a combination of TMZ chemotherapy and gene
modiﬁed TMZ-resistant gd T cells + NK cells which we
term Drug Resistant Immunotherapy (DRI). Drug resistance
is conferred by lentivector transfer of methylguanine
methyltransferase (MGMT), enabling cytotoxic lymphocyte
function in a chemotherapy-rich environment at a time
when the tumor is maximally stressed and regulatory T cells
are depleted.
Methods: Tumor NKG2DL expression and cytotoxicity of DRI
were assessed using ﬂow cytometry. Intracranial (IC) glioma
xenografts were established in immunodeﬁcient mice using
either an unmodiﬁed (P) or a TMZ-resistant clone (T) of
human GBM-X12 primary explants. Tumor-bearing mice
were treated with an intraperitoneal 60mg/kg dose of TMZ
on days 6, 8,13, and 15 post-tumor placement and received IC
injection of 1.5 x 106DRI 1x/week x 2weeks on post-injection
days 7 and 14 or 2x/week x 2 weeks following each TMZ dose
by 4h. Control mice received non-modiﬁed cells, TMZ alone
or no therapy. Survival was assessed using Kaplan-Meier
analysis.
Results: Both GBM-X12P and X12T express stress antigens
MIC-A, MIC-B, and ULBP-4. DRI cells tested for potency in
vitro killed both tumors at approximately 80% at an effector:
target ratio of 20:1 and showed no evidence of toxicity
against cultured human astrocytes. Cell therapy alone did not
improve survival beyond that of untreated mice for either
tumor. For the unmodiﬁed parent tumor X12P, both TMZ
therapy and TMZ + DRI signiﬁcantly improved survival over
untreated controls (p < 0.0001), and the combined therapy
increased median survival from 57 to 75 days over TMZ
alone. Combined therapy with TMZ + DRI also marginally
improved survival for X12T (p ¼ 0.0147) extending median
survival over TMZ alone from 22 to 27 days (p ¼ 0.0966).
Keeping the TMZ dosing schedule constant, intensiﬁcation
of DRI therapy from 1x/week to 2x/week increased
median survival from 22 days to 38 days over untreated
animals (p ¼ 0.0004) and signiﬁcantly improved median
survival over TMZ-treated animals from 27 to 38 days
(p ¼ 0.0017) with 10% of animals showing long-term
survival.Conclusions: The combination of chemotherapy-induced
tumor stress and targeted DRI signiﬁcantly increases time to
progression and improves survival in immunodeﬁcient
mice bearing otherwise impervious temozolomide-resistant
human xenograft tumors.327
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Neuroblastoma is the most common solid tumor in pediatric
patients, with a clear unmet need as survival rates are <20%
for stage IV disease. As adjuvant immunotherapy is
considered to have additional anti-tumor activity we aim to
increase cytotoxic T lymphocyte (CTL)-mediated immune
surveillance in neuroblastoma patients by administration of
a dendritic cell-based vaccine. Neuroblastoma has developed
mechanisms to circumvent CTL recognition; therefore it is
our aim to ﬁnd clinical strategies to make neuroblastoma
susceptible for CTL killing. PRAME is highly expressed in
stage IV primary neuroblastoma and PRAME-derived
antigenic peptide can be presented as peptide/MHC I
complexes to reactive T cells. LowMHC I expression levels on
neuroblastoma cells enable them to escape CTL recognition,
but MHC I levels can be increased by interferon-gamma
(IFNg). Because of the clinical toxic effects of IFNg adminis-
tration, we attempted to deliver IFNg to neuroblastoma via
alternative routes. We added natural killer (NK) cells which
recognize target cells by their lack of MHC I and found that
NK cell recognition of neuroblastoma cells upregulated class
I MHC surface expression. This effect was contact-dependent,
however could thereafter be transferred to “naïve” neuro-
blastoma cells through replacement of culture supernatant.
Interestingly, IFNg was not detected in the supernatants,
suggesting a different factor that triggers the MHC I
upregulation in neuroblastoma. Importantly, PRAME-speciﬁc
T cells were speciﬁcally activated by neuroblastoma cells
after exposure to NK cells. In conclusion; we showed that NK
cells can regulate MHC I levels on neuroblastoma cells which
transforms them into CTL targets.STEM CELL BIOLOGY328
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